Lecanemab可能提前将阿尔茨海默氏病的发病速度减慢8.3年, Lecanemab may slow Alzheimer’s progression by up to 8.3 years if given early, but isn’t available on NHS due to cost.

在CTAD会议上提出的现实世界研究表明,阿尔茨海默氏病的药物 Lecanemab, 或Leqembi, 早期给予低脑氨基甲状腺素水平的病人后, 可能会将疾病发展速度减慢8.3年。 A real-world study presented at the CTAD conference suggests the Alzheimer’s drug lecanemab, or Leqembi, may slow disease progression by up to 8.3 years when given early to patients with low brain amyloid levels. 尽管联合王国批准了该药物,但该药物无法在国民保健制度上提供,因为国家环境卫生委员会发现其好处太小,无法证明其高昂费用的合理性,估计每年全国保健服务开支为5亿英镑至10亿英镑。 Despite approval in the UK, the drug is not available on the NHS because NICE found its benefits too modest to justify its high cost, estimating annual NHS expenses at £500 million to £1 billion. 药物针对大脑中的类固醇累积,是旨在减慢早期阿尔茨海默氏病的几种新治疗方法之一。 The drug targets amyloid buildup in the brain and is one of several new treatments aimed at slowing early-stage Alzheimer’s. 另一种类似的药物,即Donanemab,也获得批准,但没有得到资助。 Another similar drug, donanemab, also approved but not funded. 研究人员和倡导团体强调,早期诊断至关重要,因为联合王国估计有100万痴呆病人的三分之一以上仍未诊断。 Researchers and advocacy groups stress that early diagnosis is critical, as over a third of the UK’s estimated one million dementia patients remain undiagnosed. 目前已有130多种阿尔茨海默病药物处于临床试验阶段，专家敦促英国改进诊断体系并为未来治疗做准备。 With over 130 Alzheimer’s drugs in trials, experts urge the UK to improve diagnosis systems and prepare for future treatments.